QNCX — Quince Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
$31.96
-$0.15 (-0.47%)
Quince Therapeutics, Inc. (QNCX) is a biotechnology company listed on NASDAQ. It is led by Dirk Thye M.D., based in 611 Gateway Boulevard, South San Francisco, CA, United States, 94080, with about 36 employees. Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Net income was -$13.4M. QNCX currently screens at market cap $79.3M.
Use this QNCX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the QNCX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the QNCX SEC filings page. Lician reads the product cache first so this HTML stays unique to Quince Therapeutics, Inc. even when a live quote feed is slow.
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
QNCX Key Statistics
Market Cap
$79.25M
Volume
17,118
Previous Close
$33.48
Day Range
$30.93 – $33.69
EPS
-$1.31
Revenue
$0.00
Net Income
-$56.83M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
36
QNCX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$56.83M | -$31.39M | -$51.66M | -$89.94M |
| EPS (Diluted) | -$1.31 | -$0.84 | -$1.54 | -$3.03 |
Total Assets
$114.48M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
-$31.90M
Free Cash Flow
$0.00
Quince Therapeutics, Inc. Company Information
- CEO, Chief Medical Officer & Director
- Dirk Thye M.D.
- Headquarters
- 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
- Website
- www.quincetx.com
- Phone
- 415 910 5717
- IPO / Founded
- 2019-05-09
- Sector
- Healthcare
- Industry
- Biotechnology